SCIENTIFIC OPINION

ADOPTED: 30 September 2020
doi: 10.2903/j.efs2.2020.6279

Safety and efficacy of Correlink™ ABS1781 *Bacillus subtilis* (*Bacillus velezensis* NRRL B-67259) as a feed additive for all growing poultry species

EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Vasileios Bampidis, Giovanna Azimonti, Maria de Lourdes Bastos, Henrik Christensen, Birgit Dusemund, Maryline Kouba, Mojca Fasmon Durjava, Marta López-Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petková, Fernando Ramos, Yolanda Sanz, Roberto Edoardo Villa, Ruud Woutersen, Pier Sandro Cocconcelli, Boet Glandorf, Miguel Prieto Maradona, Maria Saarela, Jaume Galobart, Lucilla Gregoretti, Matteo Innocenti, Gloria López-Gálvez, Elisa Pettenati, Joana Revez, Konstantinos Sofianidis, Jordi Tarrés, Maria Vittoria Vettori and Rosella Brozzi

Abstract

Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Correlink™ ABS1781 *Bacillus subtilis* (hereafter designated as Correlink™ ABS1781) when used as a feed additive for chickens for fattening, turkeys for fattening, chickens reared for laying, turkeys reared for breeding and minor growing poultry species. The product under assessment is based on viable spores of a strain originally identified as *Bacillus subtilis*, which in the course of the current assessment, was reclassified as *Bacillus velezensis* NRRL B-67259. The bacterial species *B. velezensis* is considered suitable for the qualified presumption of safety (QPS) approach to safety assessment. The identity of the active agent was established and it does not harbour acquired antimicrobial resistance genes, lacks toxigenic potential and does not have the capacity to produce aminoglycosides. Following the QPS approach to safety assessment, *B. velezensis* NRRL B-67259 is presumed safe for the target species, consumers of products derived from animals fed the additive and the environment. Since no concerns are expected from the other components of the additive, Correlink™ ABS1781 is also considered safe for the target species, consumers of products derived from animals fed the additive and the environment. Correlink™ ABS1781 is not irritant to skin and eyes or a skin sensitisser but is a respiratory sensitisser. The Panel is not in the position to conclude on the efficacy of Correlink™ ABS1781 for the target species due to lack of data.

© 2020 European Food Safety Authority. *EFSA Journal* published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

**Keywords:** Zootechnical additive, Correlink™ ABS1781, *Bacillus velezensis* NRRL B-67259, safety, QPS, efficacy

**Requestor:** European Commission

**Question number:** EFSA-Q-2020-00006

**Correspondence:** feedap@efsa.europa.eu
Panel members: Giovanna Azimonti, Vasileios Bampidis, Maria de Lourdes Bastos, Henrik Christensen, Birgit Dusemund, Mojca Fasmon Durjava, Maryline Kouba, Marta López-Alonso, Secundino López Puente, Francesca Marcon, Baltasar Mayo, Alena Pechová, Mariana Petkova, Fernando Ramos, Yolanda Sanz, Roberto Edoardo Villa and Ruud Woutersen.

Acknowledgements: The Panel wishes to acknowledge the contribution of Yolanda García Cazorla to this opinion.

Legal notice: Relevant information or parts of this scientific output have been blackened in accordance with the confidentiality requests formulated by the applicant pending a decision thereon by the European Commission. The full output has been shared with the European Commission, EU Member States and the applicant. The blackening will be subject to review once the decision on the confidentiality requests is adopted by the European Commission.

Suggested citation: EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Bampidis V, Azimonti G, Bastos ML, Christensen H, Dusemund B, Kouba M, Fasmon Durjava M, López-Alonso M, López Puente S, Marcon F, Mayo B, Pechová A, Petkova M, Ramos F, Sanz Y, Villa RE, Woutersen R, Cocconcelli PS, Glandorf B, Prieto Maradona M, Saarela M, Galobart J, Gregoretti L, Innocenti M, López-Gálvez G, Pettenati E, Revez J, Sofianidis K, Tarrés J, Vettori MV and Brozzi R, 2020. Scientific Opinion on the safety and efficacy of Correlink™ ABS1781 Bacillus subtilis (Bacillus velezensis NRRL B-67259) as a feed additive for all growing poultry species. EFSA Journal 2020;18(11):6279, 11 pp. https://doi.org/10.2903/j.efsa.2020.6279

ISSN: 1831-4732

© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union.
Table of contents

Abstract ................................................................................................................................................... 1
1. Introduction ................................................................................................................................ 4
  1.1. Background and Terms of Reference ....................................................................................... 4
  1.2. Additional information ........................................................................................................ 4
2. Data and methodologies ............................................................................................................. 4
  2.1. Data ........................................................................................................................................ 4
  2.2. Methodologies ......................................................................................................................... 4
3. Assessment ................................................................................................................................. 5
  3.1. Characterisation ....................................................................................................................... 5
    3.1.1. Characterisation of the active agent ..................................................................................... 5
    3.1.2. Manufacturing process and characterisation of the additive ................................................. 5
    3.1.3. Stability and homogeneity .................................................................................................... 6
    3.1.4. Conditions of use ............................................................................................................. 6
  3.2. Safety ...................................................................................................................................... 7
    3.2.1. Safety for target animals, consumers and environment ....................................................... 7
    3.2.2. Safety for user .................................................................................................................. 7
      3.2.2.1. Conclusions on safety for the user ................................................................................... 7
  3.3. Efficacy ................................................................................................................................. 7
    3.3.1. Efficacy for chickens for fattening ...................................................................................... 7
    3.3.2. Compatibility with coccidiostats ......................................................................................... 8
    3.3.3. Conclusions on efficacy ....................................................................................................... 8
  3.4. Post-market monitoring .......................................................................................................... 8
  4. Conclusions ............................................................................................................................... 9
  5. Documentation as provided to EFSA/Chronology ..................................................................... 9
References .......................................................................................................................................... 9
Abbreviations .................................................................................................................................... 10
Annex A – Executive Summary of the Evaluation Report of the European Union Reference Laboratory for
Feed Additives on the Method(s) of Analysis for Correlink™ Bacillus subtilis ABS1781 ........................................ 11
1. Introduction

1.1. Background and Terms of Reference

Regulation (EC) No 1831/2003\(^1\) establishes the rules governing the Community authorisation of additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an application in accordance with Article 7.

The European Commission received a request from Elanco GmbH\(^2\) for authorisation of the product Correlink™ ABS1781 Bacillus subtilis (Bacillus velezensis NRRL B-67259\(^3\) ), when used as a feed additive for chickens for fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding and minor growing poultry species (category: zootechnical additives; functional group: gut flora stabilisers).

According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application to the European Food Safety Authority (EFSA) as an application under Article 4(1) (authorisation of a feed additive or new use of a feed additive). The particulars and documents in support of the application were considered valid by EFSA as of 19 March 2020.

According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and documents submitted by the applicant, shall undertake an assessment in order to determine whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety for the target animals, consumer, user and the environment and on the efficacy of the product Correlink™ ABS1781 Bacillus subtilis (Bacillus velezensis NRRL B-67259), when used under the proposed conditions of use (see Section 3.1.4).

1.2. Additional information

The additive Correlink™ ABS1781 Bacillus subtilis (hereafter referred to as Correlink™ ABS1781) is a preparation containing viable spores of Bacillus velezensis NRRL B-67259. It has not been previously authorised in the European Union.

2. Data and methodologies

2.1. Data

The present assessment is based on data submitted by the applicant in the form of a technical dossier\(^4\) in support of the authorisation request for the use of Correlink™ ABS1781 as a feed additive.

EFSA has verified the European Union Reference Laboratory (EURL) report as it relates to the methods used for the control of the active agent in animal feed. The Executive Summary of the EURL report can be found in Annex A.\(^5\)

2.2. Methodologies

The approach followed by the FEEDAP Panel to assess the safety and the efficacy of Correlink™ ABS1781 is in line with the principles laid down in Regulation (EC) No 429/2008\(^6\) and the relevant guidance documents: Guidance on studies concerning the safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012), Guidance on the identity, characterisation and conditions of use of feed additives (EFSA FEEDAP Panel, 2017a), Guidance on the assessment of the safety of feed additives for the target species (EFSA FEEDAP Panel, 2017b), Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP Panel, 2017c), Guidance on the characterisation of microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, 2017d).

---

\(^1\) Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition. OJ L 268, 18.10.2003, p. 29.

\(^2\) Elanco Animal Health, 201 South Main St, 08520, Highstown, New Jersey, US represented by Elanco GmbH, Heinz-Lohmann Str4, 27472 Cuxhaven, Germany.

\(^3\) Originally designated as Bacillus subtilis NRRL B-67259.

\(^4\) FEED dossier reference: FAD-2019-0086.

\(^5\) The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/fnrep-fad-2019-0086_correlinkabs1781.pdf

\(^6\) Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
Panel, 2018a), Guidance on the assessment of the efficacy of feed additives (EFSA FEEDAP Panel, 2018b) and Guidance on the assessment of the safety of feed additives for the environment (EFSA FEEDAP Panel, 2019).

3. Assessment

Correlink™ ABS1781 is a preparation of viable spores of a single strain of *B. velezensis* intended for use as a zootechnical additive (functional group: gut flora stabiliser) in feed for chickens for fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding and minor growing poultry species.

3.1. Characterisation

3.1.1. Characterisation of the active agent

The active agent of Correlink™ ABS1781 is a strain of unknown origin deposited at the Agricultural Research Culture Collection (NRRL) with the accession number NRRL B-67259. The strain has not been genetically modified.

The full genome of the active agent was sequenced and used for identification purposes. The taxonomic identification of the active agent as *B. velezensis* was established by digital DNA–DNA hybridisation (dDDH) against genomes of type strains of *Bacillus* species. The dDDH values showed 80.4% and 80.1% similarity when compared to the type strains *B. amyloliquefaciens* subsp. *plantarum* FZB42 (synonym *B. velezensis*) and *B. velezensis* NRRL B-41580, respectively.

The toxigenic potential of *B. velezensis* NRRL B-67259 was assessed according to the provisions of the Guidance on the characterisation of microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, 2018a,b). No lysis of Vero cells was detected, therefore, the strain is considered to be non-toxigenic.

The susceptibility of the strain to the antibiotics recommended by the FEEDAP Panel was tested by broth microdilution following the guidance mentioned above (EFSA FEEDAP Panel, 2018a). All the minimum inhibitory concentration (MIC) values determined were equal or fell below the corresponding cut-off values. Therefore, *B. velezensis* NRRL B-67259 is susceptible to the relevant antibiotics.

The whole genome sequence (WGS) of the active agent was interrogated for the presence of antimicrobial resistance (AMR) genes by a search against the CARD (criteria: perfect, strict & loose, complete genes only, 95% identity nudge used) and the ResFinder databases (thresholds: 90% identity and 60% coverage). The Panel notes that the criteria applied in the last search were less stringent than the recommended. However, considering that neither search evidenced any hit of concern and that the strain proved susceptible to all the relevant antibiotics tested, it can be concluded that *B. velezensis* NRRL B-67259 does not harbour acquired AMR genes.

Similarly, the WGS was interrogated for the presence of virulence factors comparing the genome sequences of NRRL B-67259 against the translated sequences of *Bacillus cereus* ATCC 14579 using tBLASTn (thresholds: 90% identity and 60% coverage). The search did not evidence any hit, therefore, the strain lacks the *B. cereus* virulence factors.

To exclude the capacity of the active agent to produce aminoglycosides, the supernatants from the culture of three batches of the additive were tested against reference strains (*Staphylococcus aureus* ATCC 6538, *Escherichia coli* ATCC 11229, *Bacillus cereus* ATCC 2, *Bacillus circulans* ATCC 4516, *Streptococcus pyogenes* ATCC 12344 and *Serratia marcescens* ATCC 14041). No inhibition was observed, denoting the lack of antimicrobial production, including aminoglycosides.

3.1.2. Manufacturing process and characterisation of the additive

Viable spores of *B. velezensis* NRRL B-67259 are produced by fermentation, The final additive is then produced and standardised.
to reach the minimum guaranteed concentration of $1 \times 10^{11}$ colony forming units (CFU) per gram of additive.\textsuperscript{15} Compliance with this specification was demonstrated in five batches of the additive (mean count $1.8 \times 10^{11}$ CFU/g, range $1.4 \times 10^{11}$ to $2.0 \times 10^{11}$ CFU/g).\textsuperscript{16}

Three batches of the additive were analysed for the presence of chemical and microbiological contaminants.\textsuperscript{17} Values for dioxins and the sum of dioxins and dioxin-like PCBs were $0.08$–$0.09$ ng WHO-PCDD/F-TEQ/kg and $0.11$–$0.12$ ng WHO-PCDD/F-PCB-TEQ/kg, respectively, while those for lead, cadmium, mercury, arsenic and mycotoxins were below the respective limits of detection (LOD).\textsuperscript{18} Similarly counts of \textit{Bacillus cereus}, Enterobacteriaceae, yeasts and filamentous fungi were also below the LOD and \textit{Salmonella} spp. was absent in 25 g.\textsuperscript{19}

Correlink\textsuperscript{TM} ABS1781 is a dry preparation. The dusting potential of three batches of the additive, tested using the Stauber–Heubach method showed values of $0.06$–$0.36$ g/m$^3$.\textsuperscript{20} The particle size of the same three batches of the additive, measured by laser diffraction, showed that approximately 37–39% of the particles have diameters < 50 µm and 7–8% of the particles have diameters < 10 µm.

### 3.1.3. Stability and homogeneity

The shelf-life of the additive ($1.75 \times 10^{11}$ CFU/g) was determined by monitoring three batches stored in the original packaging (aluminium foil laminate bags) at 25°C/60% relative humidity (% RH) and 30°C/65% RH for a period of 24 months and at 40°C/75% RH for a period of 18 months.\textsuperscript{21} No reduction in total bacilli count (< 0.5 log) was observed at any condition during the experimental periods.

Three batches of the additive were individually mixed into a standard chicken vitamin/mineral premixture (containing 907 mg choline chloride/kg) at the proposed conditions of use and samples were stored for six months at three conditions (25°C/60% RH, 30°C/65% RH and 40°C/ambient RH).\textsuperscript{22} The results after six months showed no reduction in bacilli counts at any tested condition.

To investigate the stability of the additive during pelleting, samples from three batches of the additive were incorporated into a typical mash feed for chickens (maize and soybean meal) at a concentration of $1.5 \times 10^8$ CFU/kg feed and subjected to two different pelleting conditions (80–85°C and 90–95°C).\textsuperscript{23} The bacilli counts were determined before and after the pelleting treatment and at the end values were < 0.5 log compared to initial counts. To investigate the stability of the additive in complete feed, sub-samples of the samples described above were collected before and after pelleting, and stored for up to 3 months at 25°C/60% RH and 40°C/ambient RH. Essentially no reduction in bacilli counts was seen in either the mash or pelleted feed at any conditions after 3 months storage.

To examine the capacity of homogenous distribution of the additive in feed, a total of ten sub-samples were taken from the mash feed\textsuperscript{23} and the premixture\textsuperscript{22} described above. The coefficient of variation was < 1% for both mash feed and premixture.

### 3.1.4. Conditions of use

Correlink\textsuperscript{TM} ABS1781 is intended to be used in feed for chickens for fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding and minor growing poultry species at the minimum concentration of $1.5 \times 10^8$ CFU/kg complete feedstuffs.

The applicant is also asking for the authorisation to use the additive simultaneously with the authorised coccidiostats: diclazuril, decoquinate, halofuginone, monensin, salinomycin, narasin, robenidine, maduramicin and lasalocid.
3.2. Safety

3.2.1. Safety for target animals, consumers and environment

The bacterial species *B. velezensis* is considered by EFSA to be suitable for the qualified presumption of safety approach to safety assessment (EFSA, 2007; EFSA BIOHAZ Panel, 2020). This approach requires the identity of the strain to be conclusively established and evidence provided that it does not harbour acquired AMR genes, that it lacks toxigenic potential and it does not have the capacity to produce aminoglycosides. In the view of the FEEDAP Panel, the identity of the active agent was established and the compliance with the other qualifications confirmed. Therefore, the FEEDAP Panel concludes that the *B. velezensis* NRRL B-67259 does not raise safety concerns for the target species, consumers of products derived from animals fed the additive and the environment. Since no concerns are expected from the other components of the additive, Correlink™ ABS1781 is also considered safe for the target species, consumers of products derived from animals fed the additive, and the environment.

3.2.2. Safety for user

The skin\(^{24}\) and eye\(^{25}\) irritation potential of Correlink™ ABS178 was tested in valid studies performed according to OECD guidelines 404 and 405, respectively. The results showed that the additive is not a skin or eye irritant.

In a valid skin sensitisation study following OECD guideline 406, Correlink™ ABS1781 did not show any skin sensitisation potential.\(^{26}\)

The dusting potential tested (up to 0.36 g/m\(^3\)) suggests that exposure by inhalation is possible. Owing to the proteinaceous nature of the active agent, Correlink™ ABS1781 should be considered a respiratory sensitisier.

3.2.2.1. Conclusions on safety for the user

Correlink™ ABS1781 is not irritant to skin and eyes or a skin sensitisier. Owing to the proteinaceous nature of the active agent, Correlink™ ABS1781 should be considered a respiratory sensitisier.

3.3. Efficacy

3.3.1. Efficacy for chickens for fattening

A total of three trials conducted with chickens for fattening were submitted. However, two of them were not further considered due to the contamination of the control diets with the additive under assessment. In the first case\(^{27}\) the total bacilli counts in the starter, grower and finisher diets of both the control and treated groups were equivalent (i.e. control: 0.7/0.4/0.9 \(\times 10^8\) CFU/kg feedingstuffs vs Correlink™ ABS1781: 1.4/1.1/8.4 \(\times 10^8\) CFU/kg feedingstuffs). The presence of the active agent in all diets was confirmed by analysis using, according to the applicant, a strain-specific PCR targeting a functional gene of *B. velezensis* NRRL B-67259. Therefore, it can be inferred that the control diets were contaminated with the additive. In the second case\(^{28}\) the total bacilli counts in the diets of both the control and treated groups were also equivalent (i.e. control: 0.3/0.3/0.4 \(\times 10^8\) CFU/kg feedingstuffs vs Correlink™ ABS1781: 1.7/3.2/4.0 \(\times 10^8\) CFU/kg feedingstuffs), but the presence of *B. velezensis* NRRL B-67259 could not be confirmed due to the non-availability of samples. However, considering the similarities between the trials (i.e. they were both ran in the same trial site and with the same design), and that *B. velezensis* NRRL B-67259 was identified using the method mentioned above in faecal samples collected from both treatment groups, it cannot be excluded that also in this case the control diets were contaminated with the additive.

In the only trial considered, 576 one-day-old male birds (Ross 308) were fed either a non-supplemented diet (control) or a diet containing Correlink™ ABS1781 at 1.5 \(\times 10^8\) CFU/kg complete feed (confirmed by analysis, Table 1).\(^{29}\) The wheat, soybean meal and barley-based diets in mash form

---

\(^{24}\) Technical dossier/Section III/Annex III 3.1.2.1.

\(^{25}\) Technical dossier/Section III/Annex III 3.1.2.2.

\(^{26}\) Technical dossier/Section III/Annex III 3.1.2.3.

\(^{27}\) Technical dossier/Section IV/Annex IV.3.2 and Supplementary information May 2020/Annex IV.3.2.1.

\(^{28}\) Technical dossier/Section IV/Annex IV.3.2 and Supplementary information May 2020/Annexes IV.3.3.1 and 3.3.2.

\(^{29}\) Technical dossier/Section IV/Annex IV.3.1.
were administered for 42 days. The health and mortality were monitored throughout the study and the body weight (on days 0, 11, 25, 35 and 42) and feed intake were recorded. Feed to gain ratio was calculated. The data were analysed with a two-sided t-test. The pen was the experimental unit for all parameters. The significance level was set at \( p < 0.05 \). Results are presented in Table 2.

### Table 1: Trial design and dosages of the efficacy trials performed in chickens for fattening

| Total no of animals (animals per replicates) | Breed (duration) | Composition feed (Form) | Treatment groups | Analysed bacilli counts (CFU/kg feed) |
|----------------------------------------------|------------------|-------------------------|------------------|--------------------------------------|
| 576 (12)                                     | Ross 308 Males (42 days) | Wheat, soybean meal, barley (Mash) | Control Correlink\textsuperscript{TM} ABS1781 | 2.7/3.4/3.2 \times 10^6 1.5/1.6/1.7 \times 10^6 |
| 24                                          |                  |                         |                  |                                      |

### Table 2: Effects of Correlink\textsuperscript{TM} ABS1781 on the performance of chickens for fattening at 42 days of age

| Treatment groups | Daily feed intake (g) | Final body weight (kg) | Average daily weight gain (g) | Feed to gain ratio | Mortality and culling (%) |
|------------------|-----------------------|------------------------|------------------------------|--------------------|--------------------------|
| Control          | 115.8                 | 2.95                   | 71.5                         | 1.62               | 4.2                      |
| Correlink\textsuperscript{TM} ABS1781 | 118.4                 | 3.04                   | 73.0                         | 1.62               | 3.1                      |

No significant differences were observed in any of the parameters evaluated at the end of the efficacy trial. Therefore, no conclusions can be drawn on the efficacy of Correlink\textsuperscript{TM} ABS1781 for chickens for fattening.

### 3.3.2. Compatibility with coccidiostats

An in vitro study was conducted to support the compatibility of \( B. \) velezensis NRRL B-67259 with diclazuril, decoquinate, halofuginone, monensin, salinomycin, narasin, robenidine, maduramicin and lasalocid.\textsuperscript{30} The MIC values were measured using the broth microdilution method and showed values for diclazuril (> 4.8 mg/L), decoquinate (> 160 mg/L) and halofuginone (> 12 mg/L) greater than four times their maximum authorised levels in feed (1.2, 40 and 3 mg/kg, respectively). Therefore, \( B. \) velezensis NRRL B-67259 is compatible with diclazuril, decoquinate and halofuginone. The MIC values for the remaining coccidiostats (monensin and lasalocid: < 31.25 mg/L, salinomycin and narasin: < 17.5 mg/L, robenidine < 9/18 mg/L, maduramicin: 6) were below four times the corresponding maximum authorised concentrations in feed. Therefore, a demonstration of compatibility in vivo would be needed. In the absence of such studies, the Panel cannot conclude on the compatibility of \( B. \) velezensis NRRL B-67259 with monensin, lasalocid, salinomycin, narasin, robenidine and maduramicin.

### 3.3.3. Conclusions on efficacy

The FEEDAP Panel is not in the position to conclude on the efficacy of Correlink\textsuperscript{TM} ABS1781 for chickens for fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding or minor growing poultry species due to lack of data.

\( B. \) velezensis NRRL B-67259 is compatible with diclazuril, decoquinate and halofuginone. No conclusions can be drawn on the compatibility of the additive with monensin, salinomycin, narasin, robenidine, maduramicin and lasalocid.

### 3.4. Post-market monitoring

The FEEDAP Panel considers that there is no need for specific requirements for a post-market monitoring plan other than those established in the Feed Hygiene Regulation\textsuperscript{31} and Good Manufacturing Practice.

\textsuperscript{30} Technical dossier/Section II/Annex_II_4.4.1.

\textsuperscript{31} Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for feed hygiene. OJ L 35, 8.2.2005, p. 1.
4. Conclusions

Correlink™ ABS1781 is considered safe for the target species, consumers of products derived from animals fed the additive and the environment.

Correlink™ ABS1781 is not irritant to skin and eyes or a skin sensitiser, but is a respiratory sensitiser. The Panel is not in the position to conclude on the efficacy of Correlink™ ABS1781 for chickens for fattening, chickens reared for laying, turkeys for fattening, turkeys reared for breeding or minor growing poultry species due to lack of data.

_Bacillus velezensis_ NRRL B-67259 is compatible with diclazuril, decoquinate and halofuginone. No conclusions can be drawn on the compatibility of the additive with monensin, salinomycin, narasin, robenidine, maduramicin and lasalocid.

5. Documentation as provided to EFSA/Chronology

| Date       | Event                                                                 |
|------------|-----------------------------------------------------------------------|
| 06/05/19   | Reception mandate from the European Commission                        |
| 09/12/19   | Dossier received by EFSA. Correlink™ (Bacillus velezensis NRRL B-67257) as a feed additive for all growing poultry species. Submitted by Elanco GmbH |
| 19/03/20   | Application validated by EFSA – Start of the scientific assessment     |
| 23/04/20   | Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation (EC) No 1831/2003 – Scientific assessment suspended. Issues: characterization, efficacy |
| 25/05/20   | Reception of supplementary information from the applicant - Scientific assessment re-started |
| 19/06/20   | Comments received from Member States                                   |
| 25/05/20   | Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives |
| 30/09/20   | Opinion adopted by the FEEDAP Panel. End of the Scientific assessment  |

References

EFSA (European Food Safety Authority), 2007. Opinion of the Scientific Committee on a request from EFSA on the introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA. EFSA Journal 2007;5(12):587, 16 pp. [https://doi.org/10.2903/j.efsa.2007.587](https://doi.org/10.2903/j.efsa.2007.587)

EFSA BIOHAZ Panel (EFSA Panel on Biological Hazards), Koutsoumanis K, Allende A, Alvarez-Ordóñez A, Bolton D, Bover-Cid S, Chemaly M, Davies R, De Cesare A, Hilbert F, Lindqvist R, Nauta M, Peixe L, Ru G, Simmons M, Skandamis P, Suffredini E, Cocconcelli PS, Fernández Escámez PS, Maradona MP, Querol A, Suarez JE, Sundh I, Vlak J, Barizzone F, Correia S and Herman L, 2020. Scientific Opinion on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA (2017–2019). EFSA Journal 2020;18(2):5966, 56 pp. [https://doi.org/10.2903/j.efsa.2020.5966](https://doi.org/10.2903/j.efsa.2020.5966)

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2012. Guidance on studies concerning the safety of use of the additive for users/workers. EFSA Journal 2012;10(1):2539, 5 pp. [https://doi.org/10.2903/j.efsa.2012.2539](https://doi.org/10.2903/j.efsa.2012.2539)

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2017a. Guidance on the identity, characterisation and conditions of use of feed additives. EFSA Journal 2017;15(10):5023, 12 pp. [https://doi.org/10.2903/j.efsa.2017.5023](https://doi.org/10.2903/j.efsa.2017.5023)

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2017b. Guidance on the assessment of the safety of feed additives for the target species. EFSA Journal 2017;15(10):5021, 19 pp. [https://doi.org/10.2903/j.efsa.2017.5021](https://doi.org/10.2903/j.efsa.2017.5021)

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), 2017c. Guidance on the assessment of the safety of feed additives for the consumer. EFSA Journal 2017;15(10):5022, 17 pp. [https://doi.org/10.2903/j.efsa.2017.5022](https://doi.org/10.2903/j.efsa.2017.5022)
EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Rychen G, Aquilina G, Azimonti G, Bampidis V, Bastos ML, Bories G, Chesson A, Cocconcelli PS, Flachowsky G, Gropp J, Kolar B, Koubá M, López-Alonso M, López Puente S, Mantovani A, Mayo B, Ramos F, Saarela M, Villa RE, Wallace RJ, Wester P, Glandorf B, Herman L, Kärenlampi S, Aguilera J, Anguita M, Brozzi R and Galobart J, 2018a. Guidance on the characterisation of microorganisms used as feed additives or as production organisms. EFSA Journal 2018;16(3):5206, 24 pp. https://doi.org/10.2903/j.efsa.2018.5206

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Rychen G, Aquilina G, Azimonti G, Bampidis V, Bastos ML, Bories G, Chesson A, Cocconcelli PS, Flachowsky G, Gropp J, Kolar B, Koubá M, López-Alonso M, López Puente S, Mantovani A, Mayo B, Ramos F, Saarela M, Villa RE, Wallace RJ, Wester P, Anguita M, Galobart J, Innocenti ML and Martino L, 2018b. Guidance on the assessment of the efficacy of feed additives. EFSA Journal 2018;16(5):5274, 25 pp. https://doi.org/10.2903/j.efsa.2018.5274

EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed), Bampidis V, Bastos ML, Christensen H, Dusemund B, Koubá M, Kos Durjava M, López-Alonso M, López Puente S, Marcon F, Mayo B, Pechová A, Petkova M, Ramos F, Sanz Y, Villa RE, Woutersen R, Brock T, Knecht J, Kolar B, Beelen P, Padovani L, Tarrés-Call J, Vettori MV and Azimonti G, 2019. Guidance on the assessment of the safety of feed additives for the environment. EFSA Journal 2019;17(4):5648, 78 pp. https://doi.org/10.2903/j.efsa.2019.5648

**Abbreviations**

| Acronym | Description |
|---------|-------------|
| AMR     | antimicrobial resistance |
| BW      | body weight |
| CFU     | colony forming unit |
| dDDH    | digital DNA–DNA hybridisation |
| EURL    | European Union Reference Laboratory |
| EFSA FEEDAP Panel | EFSA Panel on Additives and Products or Substances used in Animal Feed |
| LOD     | limit of detection |
| MIC     | minimum inhibitory concentration |
| OECD    | Organisation for Economic Co-operation and Development |
| PCB     | polychlorinated biphenyl |
| PCDD/F  | polychlorinated dibenzo-p-dioxin and dibenzofuran |
| PFGE    | pulsed field gel electrophoresis |
| QPS     | qualified presumption of safety |
| RH      | relative humidity |
| TEQ     | toxic equivalent |
| WGS     | whole genome sequence |
| WHO     | World Health Organization |
Annex A – Executive Summary of the Evaluation Report of the European Union Reference Laboratory for Feed Additives on the Method(s) of Analysis for Correlink™ Bacillus subtilis ABS1781

In the current application authorisation is sought under Article 4(1) for Bacillus subtilis ABS1781 under the category/functional group 4(b) ‘zootechnical additives’/‘gut flora stabilisers’, according to Annex I of Regulation (EC) No 1831/2003. The authorisation is sought for the use of the feed additive for all growing poultry species.

According to the Applicant, the feed additive contains as active substance viable spores of the non-genetically modified strain Bacillus subtilis ABS1781. The feed additive is to be marketed as a dry preparation containing a minimum content of active substance of $1 \times 10^{11}$ Colony Forming Unit (CFU)/g and to be used directly in feedingstuffs or through premixtures at a minimum dose of $1.5 \times 10^5$ CFU/g complete feedingstuffs.

For the identification of Bacillus subtilis ABS1781, the EURL recommends for official control Pulsed Field Gel Electrophoresis (PFGE), a generally recognised methodology for the genetic identification of bacterial strains.

For the enumeration of Bacillus subtilis ABS1781 in the feed additive, premixtures and feedingstuffs, the Applicant submitted a pour plate count method, which was single-laboratory validated and further verified. However, the EURL is aware of the ring-trial validated spread plate EN 15784 method developed to enumerate and differentiate spores of several Bacillus spp. Furthermore, the Applicant confirmed, upon request of the EURL, the suitability of the EN 15784 method for this product.

Based on the performance characteristics reported and the applicability statement provided by the Applicant, the EURL recommends the ring-trial validated EN 15784 method for official control for the enumeration of Bacillus subtilis ABS1781 in the feed additive, premixtures and feedingstuffs.

Further testing or validation of the methods to be performed through the consortium of National Reference Laboratories as specified by Article 10 (Commission Regulation (EC) No 378/2005), as last amended by Regulation (EU) 2015/1761) is not considered necessary.

---

32 Now designated as Bacillus velezensis.
33 This is an in-house identifier used by the applicant. The correct deposition number is Bacillus velezensis NRRL B-67257.